Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AstraZeneca's ADC disappoints - on severe adverse events

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 27, 2024 5:16pm

71 Views

Post# 36109753

RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

Today's news oer the FDA rejecting Daiichi Sankyo's Merck & Co. - partnered ADV raises questions about why companies of Merck and Daiichi’s stature couldn’t get such a seemingly technical issue right first time, especially after making such a large investment in the project. So don't go off about something simple like ONCY's POA SEC filing when Big Pharma can't seem to get thing right on more important things.

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – July 3, 2024